{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '7.2.2.', 'Evaluation of SAEs (Amended 19 October 2018)', '7.2.2.1.', 'Active questioning to detect SAEs', 'Each subject/ will be instructed to contact the investigator immediately should the subject', 'manifest any signs and symptoms (s)he perceives/ they perceive as serious. However, an', 'occurrence of severe AECOPD is not defined as an SAE and therefore does not need to', 'be reported as such, unless in the opinion of the Investigator this is related to a study', 'procedure.', 'All SAEs either observed by the investigator or his/ her staff or reported by the subject', 'spontaneously or in response to a direct question will be evaluated by the investigator.', 'The nature of each event, date and time of onset, outcome, intensity and possible', 'relationship to the study procedures should be established.', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (e.g., hospital progress notes, laboratory and diagnostics reports) relative', 'to the event. The investigator will then record all relevant information regarding the', \"AE/SAE in the eCRF. The investigator is not allowed to send photocopies of the subject's\", 'medical records to GSK Biologicals instead of appropriately completing the eCRF.', 'However, there may be instances when copies of medical records for certain cases are', 'requested by GSK Biologicals. In this instance, all subject identifiers will be blinded on', 'the copies of the medical records prior to submission to GSK Biologicals.', 'The investigator will attempt to establish a diagnosis pertaining to the event based on', 'signs, symptoms, and/ or other clinical information. In such cases, the diagnosis should', 'be documented as the AE/SAE and not the individual signs/symptoms.', '7.2.2.2.', 'Assessment of causality', 'The investigator should assess the causality of each SAE. The investigator will use', 'clinical judgement to determine the relationship between the SAEs and study', 'participation. Alternative causes, such as natural history of the underlying diseases, other', 'concomitant therapy and other risk factors will be considered and investigated.', 'There may be situations when a SAE has occurred and the investigator has minimal', 'information to include in the initial report to GSK Biologicals. However, it is very', 'important that the investigator always makes an assessment of causality for every event', 'prior to submission of the SAE report to GSK Biologicals. The investigator may change', 'his/her opinion of causality in light of follow-up information and update the SAE', 'information accordingly.', 'If an event meets the criteria to be considered as \"serious\\' (see section 7.1.2), additional', 'examinations/tests will be performed by the investigator in order to determine ALL', 'possibly contributing factors to each SAE.', '19-OCT-2018', '62', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Possibly contributing factors include:', 'Medical history.', 'Concomitant medication.', 'Protocol required procedure.', 'Other procedure not required by the protocol.', '7.2.2.3.', 'Assessment of outcomes', 'The investigator will assess the outcome of all AEs (including SAEs) recorded during the', 'study as:', 'Recovered/ resolved.', 'Recovering/resolving.', 'Not recovered/ not resolved.', 'Recovered with sequelae/ resolved with sequelae.', 'Fatal (SAEs only).', '7.3.', 'Reporting of SAEs', '7.3.1.', 'Prompt reporting of SAEs related to study participation to GSK', 'SAEs that occur in the time period defined in Section 7.2.1 will be reported promptly to', 'GSK within the timeframes described in Table 11 once the investigator determines that', 'the event meets the protocol definition of an SAE.', 'Table 11', 'Timeframes for submitting SAEs related to study participation to', 'GSK', 'Follow-up of relevant information', 'Initial reports', 'Type of event', 'on a previous report', 'Timeframe', 'Documents', 'Timeframe', 'Documents', 'SAEs related to study', '24 hours*', 'Electronic/', '24 hours*', 'Electronic/', 'participation', 'Expedited Adverse', 'Expedited Adverse Event Report', 'Event Report', '*', 'Timeframe allowed after receipt or awareness of the information.', '7.3.2.', 'Contact information for reporting SAEs to GSK', 'Back-up Study Contact for Reporting SAEs', '24/24 hour and 7/7 day availability:', 'GSK Biologicals Clinical Safety & Pharmacovigilance', 'Fax:', 'PPD', 'PPD', 'or', '19-OCT-2018', '63', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}